ArticleNoro psikiyatri arsivi2026
Sex-Dependent Effects of Rivastigmine on Melatonin Receptors in Middle-Aged Rats.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Melatonin (5-methoxy-N-acetyltryptamine) is closely linked to the body's natural circadian rhythm. Dementia is significantly more common among older individuals. Rivastigmine (RIVA) functions as a reversible inhibitor of acetylcholinesterase and butyrylcholinesterase, prescribed to help alleviate the symptoms of dementia. The mechanism behind RIVA's neuroendocrine interactions remains unclear despite its efficacy in treating specific symptoms. Our research aimed to investigate the effects of RIVA on memory, anxiety, and the expression of melatonin receptor genes MT1 and MT2 in middle-aged, 13-month-old male and female rats. Methods: Rats were administered intraperitoneal injections of 2 mg/kg RIVA or saline once a day for ten days in succession. Twenty-four hours after the final injection, rats underwent the Y-maze and elevated plus maze tests, after which tissue samples were collected for qPCR analysis. Results: Behavioral tests revealed sex-specific responses; elevated plus maze test results indicated that RIVA did not alter exploratory behavior in female rats but decreased it in male rats compared to controls. At the same time, RIVA treatment resulted in significant decreases of MT1 and MT2 gene expression in the hippocampus of both sexes, but cortical expression showed different patterns in males and system. Conclusion: RIVA treatment in middle-aged rats may cause changes in MT1 and MT2 gene expression concomitant with behavioral alterations. The variation in melatonin receptor expression across sexes indicates a potential sex-dependent impact in aging populations, suggesting an interaction between cholinergic and melatonergic systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.